1. Pillai S, Gopalan V, Smith RA, Lam AK. Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era. Crit Rev Oncol Hematol. 2016; 100:190–208. PMID:
26839173.
2. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014; 99:1915–1942. PMID:
24893135.
3. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005; 366:665–675. PMID:
16112304.
4. Chen H, Sippel RS, O'Dorisio MS, Vinik AI, Lloyd RV, Pacak K, et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010; 39:775–783. PMID:
20664475.
5. Galan SR, Kann PH. Genet ics and molecular pathogenesis of pheochromocytoma and paraganglioma. Clin Endocrinol (Oxf). 2013; 78:165–175. PMID:
23061808.
6. Cunningham SC, Suh HS, Winter JM, Montgomery E, Schulick RD, Cameron JL, et al. Retroperitoneal paraganglioma: single-institution experience and review of the literature. J Gastrointest Surg. 2006; 10:1156–1163. PMID:
16966036.
7. Ji XK, Zheng XW, Wu XL, Yu ZP, Shan YF, Zhang QY, et al. Diagnosis and surgical treatment of retroperitoneal paraganglioma: a single-institution experience of 34 cases. Oncol Lett. 2017; 14:2268–2280. PMID:
28789448.
8. Xu W, Li H, Ji Z, Yan W, Zhang Y, Zhang X, et al. Retroperitoneal laparoscopic management of paraganglioma: a single institute experience. PLoS One. 2016; 11:e0149433. PMID:
26885838.
9. Walz MK, Alesina PF, Wenger FA, Koch JA, Neumann HP, Petersenn S, et al. Laparoscopic and retroperitoneoscopic treatment of pheochromocytomas and retroperitoneal paragangliomas: results of 161 tumors in 126 patients. World J Surg. 2006; 30:899–908. PMID:
16617419.
10. Wang J, Li Y, Xiao N, Duan J, Yang N, Bao J, et al. Retroperitoneoscopic resection of primary paraganglioma: single-center clinical experience and literature review. J Endourol. 2014; 28:1345–1351. PMID:
24955712.
11. Alemanno G, Bergamini C, Somigli R, Prosperi P, Bruscino A, Valeri A. Abdominal paragangliomas: a quantitative prognostic score as predictive factor of the feasibility of the laparoscopic approach. Updates Surg. 2017; 69:509–515. PMID:
28537037.
12. Kang SW, Kandil E, Kim MJ, Kim KS, Lee CR, Jeong JJ, et al. Posterior retroperitoneoscopic resection of extra-adrenal paraganglioma located in the aorto-caval space. Ann Surg Oncol. 2018; 25:963. PMID:
29330717.
13. Williams MD. Paragangliomas of the head and neck: an overview from diagnosis to genetics. Head Neck Pathol. 2017; 11:278–287. PMID:
28321772.
14. Thompson LD. Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol. 2002; 26:551–566. PMID:
11979086.
15. Wu D, Tischler AS, Lloyd RV, DeLellis RA, de Krijger R, van Nederveen F, et al. Observer variation in the application of the Pheochromocytoma of the Adrenal Gland Scaled Score. Am J Surg Pathol. 2009; 33:599–608. PMID:
19145205.
16. Koh JM, Ahn SH, Kim H, Kim BJ, Sung TY, Kim YH, et al. Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma. PLoS One. 2017; 12:e0187398. PMID:
29117221.
17. Kimura N, Takayanagi R, Takizawa N, Itagaki E, Katabami T, Kakoi N, et al. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2014; 21:405–414. PMID:
24521857.